Fenebrutinib First Drug in a Decade to Slow PPMS Disability
Fenebrutinib numerically reduced the risk of disability progression by 12% compared to Ocrevus as early as 24 weeks; additional analysis showed potential benefit in upper limb function Genentech, part...
